Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | TNF | P01375 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.44 |
| ▸ | PDE5A | O76074 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
| ▸ | TOP2A | P11388 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10149309 | 0.87 | L3MBTL1 (0.47) | FAAHALDH1A1NAMPTL3MBTL1PDK2 | |
| SCHEMBL10439151 | 0.84 | SMN1; SMN2 (0.55) | GAAALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL562604 | 0.82 | L3MBTL1 (0.53) | ALDH1A1SMN1; SMN2L3MBTL1PDK2 | |
| SCHEMBL13434311 | 0.81 | LMNA (0.47) | GAASMN1; SMN2TNF | |
| SCHEMBL415823 | 0.79 | TNF (0.46) | GAATNF | |
| SCHEMBL10247836 | 0.77 | ALDH1A1 (0.55) | GAAFAAHALDH1A1TNFPDE5A | |
| Biphenyl SCHEMBL27395713 | 0.76 | CYP4F2 (0.54) | GAAFAAHALDH1A1SMN1; SMN2PDE5A | |
| SCHEMBL17265623 | 0.75 | L3MBTL1 (0.44) | TNFL3MBTL1 | |
| Succinic Acid Diethyl Ester SCHEMBL27940678 | 0.75 | SMN1; SMN2 (0.62) | ALDH1A1SMN1; SMN2PTPN1TOP2A | |
| SCHEMBL15453773 | 0.75 | NR4A2 (0.44) | ALDH1A1NAMPTL3MBTL1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140371216-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORPORATION (US) | 2014-12-18 | — | — | US | disclosed |
| US-8703783-B2 | Purinone derivatives as HM74A agonists | INCYTE CORPORATION (US) | 2014-04-22 | — | — | US | disclosed |
| CN-101466714-B | Purinone derivatives as HM74A agonists | INCYTE CORP | 2013-02-06 | — | — | CN | disclosed |
| US-20120035172-A1 | Purinone Derivatives as HM74A Agonists | INCYTE CORPORATION (US) | 2012-02-09 | — | — | US | disclosed |
| US-8039478-B2 | Purinone derivatives as HM74A agonists | INCYTE CORPORATION (US) | 2011-10-18 | — | — | US | disclosed |
| US-20090286774-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| CN-101466714-A | Purinone derivatives as HM74A agonists | INCYTE CORP (US) | 2009-06-24 | — | — | CN | disclosed |
| EP-2044074-A2 | PURINONE DERIVATIVES AS HM74A AGONISTS | Incyte Corporation (US) | 2009-04-08 | — | — | EP | disclosed |
| US-7511050-B2 | hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors; avoiding adverse effects such as hepatotoxicity and cutaneous flushing; low dosage; 2-bromo-8-methyl-4-pentyl-1,4-dihydro-5H-[1,2,4]triazolo[5,1-i]purin-5-one; to treat cardiovascular disorders | INCYTE CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-20080045554-A1 | hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors; avoiding adverse effects such as hepatotoxicity and cutaneous flushing; low dosage; 2-bromo-8-methyl-4-pentyl-1,4-dihydro-5H-[1,2,4]triazolo[5,1-i]purin-5-one; to treat cardiovascular disorders | INCYTE CORPORATION (US) | 2008-02-21 | — | — | US | disclosed |
| WO-2007150025-A2 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORPORATION (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371216-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | GPR84, P2RY1, ADRA1A | GAA 3797/4885FAAH 756/4885ALDH1A1 641/4885 |
| US-20120035172-A1 | Purinone Derivatives as HM74A Agonists | GPR84, P2RY1, ADRA1A | GAA 3797/4885FAAH 756/4885ALDH1A1 641/4885 |
| US-20090286774-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | GPR84, P2RY1, ADRA1A | GAA 3797/4885FAAH 756/4885ALDH1A1 641/4885 |
| US-20080045554-A1 | hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors; avoiding adverse effects such as hepatotoxicity and cutaneous flushing; low dosage; 2-bromo-8-methyl-4-pentyl-1,4-dihydro-5H-[1,2,4]triazolo[5,1-i]purin-5-one; to treat cardiovascular disorders | HMGCR, LDLR, GPBAR1 | GAA 2491/4885FAAH 1057/4885ALDH1A1 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.